Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Receivables (2020 - 2025)

Journey Medical's Change in Receivables history spans 6 years, with the latest figure at $11.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 1674.16% year-over-year to $11.8 million, compared with a TTM value of $19.3 million through Dec 2025, up 532.2%, and an annual FY2025 reading of $19.3 million, up 532.2% over the prior year.
  • Change in Receivables for Q4 2025 was $11.8 million at Journey Medical, up from $2.4 million in the prior quarter.
  • The five-year high for Change in Receivables was $11.8 million in Q4 2025, with the low at -$10.4 million in Q2 2023.
  • Average Change in Receivables over 5 years is $346350.0, with a median of -$67000.0 recorded in 2022.
  • Biggest YoY gain for Change in Receivables was 14170.59% in 2023; the steepest drop was 10538.55% in 2023.
  • Tracing DERM's Change in Receivables over 5 years: stood at -$8.5 million in 2021, then soared by 99.4% to -$51000.0 in 2022, then skyrocketed by 14170.59% to $7.2 million in 2023, then plummeted by 110.41% to -$747000.0 in 2024, then skyrocketed by 1674.16% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's Change in Receivables are $11.8 million (Q4 2025), $2.4 million (Q3 2025), and -$2.8 million (Q2 2025).